221 related articles for article (PubMed ID: 1543196)
1. Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome.
Sawada S; Sugai S; Iijima S; Takei M; Paredes E; Hayama T; Nishinarita S; Hosokawa Y; Horie T; Obara T
Am J Med; 1992 Feb; 92(2):134-40. PubMed ID: 1543196
[TBL] [Abstract][Full Text] [Related]
2. Immunologic significance of increased soluble CD8/CD4 molecules in patients with active systemic lupus erythematosus.
Sawada S; Hashimoto H; Iijima S; Tokano Y; Takei M; Shida M; Obara T
J Clin Lab Anal; 1993; 7(3):141-6. PubMed ID: 8509943
[TBL] [Abstract][Full Text] [Related]
3. Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.
Spronk PE; ter Borg EJ; Huitema MG; Limburg PC; Kallenberg CG
Ann Rheum Dis; 1994 Apr; 53(4):235-9. PubMed ID: 8203951
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of soluble CD8 and CD4 in patients with infectious mononucleosis.
Yoneyama A; Nakahara K; Higashihara M; Kurokawa K
Br J Haematol; 1995 Jan; 89(1):47-54. PubMed ID: 7833276
[TBL] [Abstract][Full Text] [Related]
5. Changes in soluble CD4 and CD8 proteins in healthy pregnant and postpartum women.
Watanabe M; Iwatani Y; Hidaka Y; Mitsuda N; Amino N
Am J Reprod Immunol; 1996 Oct; 36(4):220-7. PubMed ID: 8911630
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to CD4 in primary Sjögren's syndrome.
Henriksson G; Manthorpe R; Bredberg A
Rheumatology (Oxford); 2000 Feb; 39(2):142-7. PubMed ID: 10725063
[TBL] [Abstract][Full Text] [Related]
7. Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis.
Hebbar M; Jeannin P; Magistrelli G; Hatron PY; Hachulla E; Devulder B; Bonnefoy JY; Delneste Y
Clin Exp Immunol; 2004 May; 136(2):388-92. PubMed ID: 15086406
[TBL] [Abstract][Full Text] [Related]
8. Serum soluble Fas/APO-1 is increased in patients with primary Sjögren's syndrome.
Fujihara T; Takeuchi T; Tsubota K; Kayagaki N; Yagita H; Okumura K; Abe T
Clin Rheumatol; 1998; 17(6):496-9. PubMed ID: 9890678
[TBL] [Abstract][Full Text] [Related]
9. Behavior of serum soluble interleukin-2 receptor, soluble CD8 and soluble CD4 in the early phases of acute pancreatitis.
Pezzilli R; Billi P; Gullo L; Beltrandi E; Maldini M; Mancini R; Incorvaia L; Miglioli M
Digestion; 1994; 55(4):268-73. PubMed ID: 8063032
[TBL] [Abstract][Full Text] [Related]
10. Increased frequency of CCR7
Wu C; Yang P; Liu H; Xiao W; Zhao L
Cytokine; 2018 Oct; 110():9-17. PubMed ID: 29684636
[TBL] [Abstract][Full Text] [Related]
11. Anti-agalactosyl IgG antibodies and isotype profiles of rheumatoid factors in Sjögren's syndrome and rheumatoid arthritis.
Ichikawa Y; Yamada C; Horiki T; Hoshina Y; Uchiyama M; Yamada Y; Toumatu J
Clin Exp Rheumatol; 1998; 16(6):709-15. PubMed ID: 9844764
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD4 and CD8 molecules in patients with systemic sclerosis.
Tokano Y; Kaneko H; Obara T; Hashimoto H; Okumura K; Hirose S
Clin Rheumatol; 1993 Dec; 12(4):490-3. PubMed ID: 8124911
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD4 and CD8 in serum from patients with localized scleroderma.
Sato S; Fujimoto M; Kikuchi K; Ihn H; Tamaki K; Takehara K
Arch Dermatol Res; 1996 Jun; 288(7):358-62. PubMed ID: 8818182
[TBL] [Abstract][Full Text] [Related]
14. Serum soluble CD4 and CD8 levels in Kawasaki disease.
Furukawa S; Matsubara T; Tsuji K; Motohashi T; Okumura K; Yabuta K
Clin Exp Immunol; 1991 Oct; 86(1):134-9. PubMed ID: 1914226
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes.
Struyf NJ; Snoeck HW; Bridts CH; De Clerck LS; Stevens WJ
Ann Rheum Dis; 1990 Sep; 49(9):690-3. PubMed ID: 1700674
[TBL] [Abstract][Full Text] [Related]
16. Impaired degradation and aberrant phagocytosis of necrotic cell debris in the peripheral blood of patients with primary Sjögren's syndrome.
Fragoulis GE; Vakrakou AG; Papadopoulou A; Germenis A; Kanavakis E; Moutsopoulos HM; Manoussakis MN
J Autoimmun; 2015 Jan; 56():12-22. PubMed ID: 25228497
[TBL] [Abstract][Full Text] [Related]
17. Comparison of antinuclear antibody and other immunohematological profiles among primary Sjögren's syndrome, secondary Sjögren's syndrome associated with rheumatoid arthritis or systemic lupus erythematosus, and corresponding systemic disease.
Ichikawa Y; Takaya M; Shimizu H; Uchiyama M; Moriuchi J; Morita K; Hoshina Y; Horiki T
Tokai J Exp Clin Med; 1993 Dec; 18(3-6):133-8. PubMed ID: 7701526
[TBL] [Abstract][Full Text] [Related]
18. Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome.
Manoussakis MN; Georgopoulou C; Zintzaras E; Spyropoulou M; Stavropoulou A; Skopouli FN; Moutsopoulos HM
Arthritis Rheum; 2004 Mar; 50(3):882-91. PubMed ID: 15022331
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases.
Goules A; Tzioufas AG; Manousakis MN; Kirou KA; Crow MK; Routsias JG
J Autoimmun; 2006 May; 26(3):165-71. PubMed ID: 16621447
[TBL] [Abstract][Full Text] [Related]
20. Quantitative defect of CD4+2H4+ cells in systemic lupus erythematosus and Sjögren's syndrome.
Sato K; Miyasaka N; Yamaoka K; Okuda M; Yata J; Nishioka K
Arthritis Rheum; 1987 Dec; 30(12):1407-11. PubMed ID: 2963643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
